tradingkey.logo
搜索

Aclarion Inc

ACON
添加自选
3.090USD
+0.070+2.32%
收盘 07/02, 13:00美东报价延迟15分钟
7.55M总市值
亏损市盈率 TTM

Aclarion Inc

3.090
+0.070+2.32%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+2.32%

5天

+8.42%

1月

-12.46%

6月

-37.95%

今年开始到现在

-32.83%

1年

-58.52%

关键数据
3.045今开
3.110最高
21.27K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.87%换手率
3.020昨收
3.020最低
48.12K成交额
亏损市盈率静
0.38市净率
0.00%股息率 TTM
-43.37%ROA
12.03052周最高
1.14量比
-7.05M净利润
2.44M总股本
-5.6302每股收益TTM
1.20Beta
-45.43%ROE
2.34052周最低
2.98%振幅
17.74%毛利率
7.55M总市值
-3.34回报/风险
4.32%风险率

TradingKey Aclarion Inc股票评分

单位: USD 更新时间: 2026-07-02

操作建议

Aclarion Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名207/387位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价7.50。中期看,股价处于下降通道。近一个月,市场表现较差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Aclarion Inc评分

相关信息

行业排名
207 / 387
全市场排名
391 / 4565
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看好

Aclarion Inc亮点

亮点风险
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
业绩增长期
公司处于发展阶段,最新年度总收入75.73K美元
利润高增长
公司净利润处于行业前列,最新年度总收入75.73K美元
估值低估
公司最新PE估值-0.55,处于3年历史低位
机构加仓
最新机构持股58.05K股,环比增加22.32%

分析师目标

根据 1 位分析师
买入
评级
7.500
目标均价
+148.34%
涨幅空间

Aclarion Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Aclarion Inc简介

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
公司代码ACON
公司Aclarion Inc
CEONess (Brent)
网址https://aclarion.com/

常见问题

Aclarion Inc(ACON)的当前股价是多少?

Aclarion Inc(ACON)的当前股价是 3.09。

Aclarion Inc的股票代码是什么?

Aclarion Inc的股票代码是ACON。

Aclarion Inc股票的52周最高点是多少?

Aclarion Inc股票的52周最高点是12.03。

Aclarion Inc股票的52周最低点是多少?

Aclarion Inc股票的52周最低点是2.34。

Aclarion Inc的市值是多少?

Aclarion Inc的市值是7.55M。

现在Aclarion Inc(ACON)的股票是买入、持有还是卖出?

根据分析师评级,Aclarion Inc(ACON)的总体评级为买入,目标价格为7.50。

Aclarion Inc(ACON)股票的每股收益(EPS TTM)是多少

Aclarion Inc(ACON)股票的每股收益(EPS TTM)是-13.61。